Literature DB >> 23299230

Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning.

Kelly Williamson1, Michael S Wahl, Mark B Mycyk.   

Abstract

There is no general consensus among clinicians on the superior route or duration of treatment with N-acetylcysteine (NAC) for acute acetaminophen (APAP) poisoning, and head-to-head studies comparing intravenous (IV) and oral NAC have not been done. Recent 20-hour IV NAC protocol failures in the United States prompted some to question its safety. Our objective was to determine if treatment with the 20-hour IV NAC protocol results in clinical outcomes different from the longer 36-hour oral or 72-hour oral NAC protocols in cases of acute APAP poisoning. We performed a retrospective analysis of all consecutive cases of acute APAP overdose where NAC treatment was initiated within 8 hours of ingestion between January 1, 2002, and December 31, 2007. Outcomes were survival, transplant, and death; secondary outcomes were based on King's College Criteria; interrater reliability was calculated with a kappa score. Out of 4642 cases of APAP overdose, 795 met study inclusion criteria: 213 were treated with 20-hour IV protocol, 213 with the 36-hour oral protocol, and 369 with the 72-hour oral protocol. The mean age in these groups was 25 years [95% confidence interval (CI): 22-26], 26 years (95%CI: 23-29), and 27 years (95%CI: 25-28), respectively. The mean 4-hour APAP concentration was 199 μg/mL (95%CI: 188-211), 174 μg/mL (95%CI: 164-184), and 205 μg/mL (95%CI: 195-216), respectively. No cases of transplant or death occurred, and secondary outcomes were rare. When administered within 8 hours of acute APAP poisoning, the 20-hour IV treatment protocol was as effective as the longer 36-hour oral and 72-hour oral treatment protocols. Further study is needed to determine outcome differences between IV and oral NAC when treatment is initiated >8 hours after overdose or in cases of coingestion with other drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299230     DOI: 10.1097/MJT.0b013e318250f829

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  8 in total

Review 1.  Evidence for the changing regimens of acetylcysteine.

Authors:  Angela L Chiew; Geoffrey K Isbister; Stephen B Duffull; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-11-23       Impact factor: 4.335

2.  It's Been a Long Journey: Do We Know Where We Are Going?

Authors:  Frank P Paloucek; Michele Zell Kanter
Journal:  J Med Toxicol       Date:  2021-04-21

3.  Impact of amending the acetylcysteine marketing authorisation on treatment of paracetamol overdose.

Authors:  G Thompson; S B Fatima; N Shah; G Kitching; W S Waring
Journal:  ISRN Toxicol       Date:  2013-07-16

4.  Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation.

Authors:  Yung-Luen Yu; Giou-Teng Yiang; Pei-Lun Chou; Hsu-Hung Tseng; Tsai-Kun Wu; Yu-Ting Hung; Pei-Shiuan Lin; Shu-Yu Lin; Hsiao-Chun Liu; Wei-Jung Chang; Chyou-Wei Wei
Journal:  Mol Med Rep       Date:  2014-03-28       Impact factor: 2.952

Review 5.  Drug-induced liver injury: Do we know everything?

Authors:  Tamara Alempijevic; Simon Zec; Tomica Milosavljevic
Journal:  World J Hepatol       Date:  2017-04-08

Review 6.  Interventions for paracetamol (acetaminophen) overdose.

Authors:  Angela L Chiew; Christian Gluud; Jesper Brok; Nick A Buckley
Journal:  Cochrane Database Syst Rev       Date:  2018-02-23

7.  Evaluation of the children with acute acetaminophen overdose and intravenous N-acetylcysteine treatment.

Authors:  Yakup Yesil; Abdurrahman Avar Ozdemir
Journal:  Pak J Med Sci       Date:  2018 May-Jun       Impact factor: 1.088

Review 8.  The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress.

Authors:  Ganesh Raghu; Michael Berk; Peter A Campochiaro; Hartmut Jaeschke; Giancarlo Marenzi; Luca Richeldi; Fu-Qiang Wen; Ferdinando Nicoletti; Peter M A Calverley
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.